German life sciences company making lab equipment and bioprocessing technology, majority owner of Sartorius Stedim Biotech.
German life sciences company making lab equipment and bioprocessing technology, majority owner of Sartorius Stedim Biotech.
Earns most of its revenue through Sartorius Stedim Biotech: equipment sold once, then consumables such as bags and filters bought again for every production batch. The smaller lab division sells balances, pipettes and filtration products to research and quality-control labs.
Moat: narrow (switching costs, installed base, process know-how). Bioprocessing/lab equipment gets validated into customer workflows, creating switching costs.
Headquarters: Gottingen, Germany · Founded: 1870 · Employees: 14,042
Size Sartorius (SRT.DE) is a Germany Health Care company (Medical Specialties) with a market value of $19.9B, the 34th largest of 198 Germany companies the cockpit tracks. Shares closed at €229.50 on 18 Nov 2026.
Performance Over six months the shares gained 25.7%, against +25.3% for the median peer and -0.9% for the Germany market (cap-weighted) — 11th highest of 21 in its peer set.
Growth Revenue grew 4.2% over the last twelve months (peer median +7.6%); the operating margin is 17.8% (peer median 17.4%).
Valuation It trades at 43.0× forward earnings against a peer median of 27.8× (6th most expensive of 20).
Price implies For today's price to make sense, revenue must grow about 26% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is +17 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 2.8 points below its cost of capital (8.5% WACC).
Credit Sartorius has 4 bonds outstanding ($3.16B), rated BBB- by the agencies and trading like BBB at a weighted spread of 110 bp.
Next results Next results expected around 23 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | €3.66B | €3.54B | €3.38B | €3.40B | €4.17B |
| Revenue growth | — | +5% | 0% | -19% | — |
| Gross profit | €1.66B | €1.64B | €1.52B | €1.57B | €2.20B |
| EBITDA | €1.08B | €1.07B | €995M | €1.00B | €1.48B |
| Net income | €218M | €155M | €84.0M | €206M | €678M |
| Free cash flow | €320M | €214M | €356M | €186M | €176M |
| Capital expenditure | €399M | €442M | €410M | €560M | €523M |
| Total debt | €3.91B | €4.28B | €4.56B | €5.31B | €2.54B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Sartorius SRT.DE | $19.9B | +26% | +4% | 18% | 43.0× | 25.6% |
| Danaher DHR | $161B | +34% | +6% | 21% | 25.1× | 20.8% |
| Thermo Fisher Scientific TMO | $257B | +53% | +8% | 19% | 25.7× | 21.3% |
| Merck KGaA MRK.DE | $71.3B | +16% | +1% | 19% | 17.4× | 7.4% |
| Repligen RGEN | $11.0B | +55% | +14% | 9% | 71.0× | 56.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | SRT.DE | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +10.1% | +5.7% | 5th highest of 21 |
| 6-month return | +25.7% | +25.3% | 11th highest of 21 |
| Distance from 52-week high | -3.4% | -11.1% | 5th highest of 21 |
| Revenue growth (TTM) | +4.2% | +7.6% | 6th lowest of 21 |
| Operating margin | 17.8% | 17.4% | 10th highest of 21 |
| Forward P/E | 43.0× | 27.8× | 6th most expensive of 20 |
| Growth the price implies (Req g, 7 yrs) | 25.6% | 14.0% | 7th most demanding of 18 |
| Growth delivered (Del g) | +8.7% | +8.3% | 9th highest of 18 |
| Hurdle (Req g minus delivered) | +16.9 pp | +4.2 pp | 6th most demanding of 18 |
| ROIC minus cost of capital | -2.8 pp | +2.2 pp | 7th lowest of 21 |
| EV / EBITDA | 21.3× | 18.5× | 8th most expensive of 17 |
| Net debt / EBITDA | 3.4× | 0.8× | 2nd most indebted of 17 |
| Bond spread | 110 bp | 94 bp | 3rd widest of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Sartorius SRT.DE | Germany | $19.9B | +26% | +4% | 18% | 43.0× | 25.6% | +8.7% |
| Sonova SOON.SW | Switzerland | $19.8B | +40% | -6% | 23% | 25.3× | 6.0% | +6.7% |
| Guardant Health GH | United States | $19.6B | +26% | +42% | -39% | n/a | n/a | n/a |
| Zimmer Biomet ZBH | United States | $19.6B | +21% | +7% | 16% | 11.7× | 7.4% | +3.2% |
| Straumann STMN.SW | Switzerland | $20.4B | +20% | +2% | 21% | 32.9× | 16.2% | +12.8% |
| Revvity RVTY | United States | $17.0B | +61% | +5% | 16% | 26.2× | 26.4% | -5.5% |
| Coloplast A/S COLO-B.CO | Denmark | $16.6B | +24% | +4% | 25% | 20.0× | -2.1% | +8.3% |
| Terumo 4543.T | Japan | $24.0B | +32% | +15% | 17% | 27.8× | 8.8% | +13.0% |
| Sartorius Stedim Biotech DIM.PA | France | $24.2B | +32% | +4% | 19% | 45.7× | 33.4% | +9.2% |
| Steris STE | United States | $25.2B | +21% | +8% | 20% | 21.9× | 14.0% | +13.8% |
| Shanghai United Imaging Healthcare 688271.SS | China | $14.4B | +4% | +27% | 9% | 45.7× | n/a | n/a |
| West Pharmaceutical Services WST | United States | $28.1B | +32% | +13% | 23% | 40.2× | 25.8% | +7.4% |
| Glaukos GKOS | United States | $13.8B | +62% | +47% | -9% | 161.5× | n/a | n/a |
| Lenskart Solutions LENSKART.NS | India | $13.6B | +49% | +35% | 10% | 137.7× | 53.2% | +33.5% |
| Baxter International BAX | United States | $13.5B | +39% | +5% | 6% | 12.7× | 13.4% | -0.7% |
| Dexcom DXCM | United States | $30.8B | +16% | +13% | 24% | 28.0× | 19.6% | +19.3% |
| Olympus 7733.T | Japan | $12.7B | +5% | +9% | 18% | 18.7× | -6.5% | +6.7% |
| Penumbra PEN | United States | $12.6B | -2% | +17% | 12% | 55.7× | 30.7% | +20.2% |
| Smith & Nephew SN..L | United Kingdom | $12.6B | +1% | +2% | 17% | 14.2× | 11.1% | +5.6% |
| Illumina ILMN | United States | $31.8B | +48% | +6% | 21% | 35.2× | 27.2% | +6.0% |
| Shenzhen Mindray Bio-Medical Electronics 300760.SZ | China | $33.6B | +15% | +5% | 28% | 27.3× | 1.0% | +9.7% |
Sartorius has 4 bonds outstanding with $3.16B face value. The agencies rate it BBB-; its bonds trade like BBB. Weighted yield 4.31%, a spread of 110 bp over government bonds.